Dear Ms. Jarzabek:

Please refer to your supplemental biologics license application, dated and received December 23, 2020, and your amendments, submitted under section 351(a) of the Public Health Service Act for PADCEV (enfortumab vedotin-ejfv) injection.

This Prior Approval supplemental biologics application provides for the addition of severe cutaneous adverse reactions including fatal cases of Stevens-Johnson syndrome and toxic epidermal necrolysis to the Dose Modification subsection 2.2, Warnings and Precaution subsection 5.1, Adverse Reactions subsection 6.2, revisions to Patient Counseling Information section 17, and Patient Information sections of the U.S. prescribing information for enfortumab vedotin-ejfv. In addition, editorial changes were made throughout the label.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the Food and Drug Administration (FDA) automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the

---

Prescribing Information and Patient Package Insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because studies are impossible or highly impracticable since the incidence of locally advanced or metastatic urothelial cancer in the pediatric population is extremely rare.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

³ For the most recent version of a guidance, check the FDA guidance web page athttps://www.fda.gov/media/128163/download.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.\footnote{http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf} Information and Instructions for completing the form can be found at FDA.gov.\footnote{http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf}

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions you may contact Felicia Diggs, Safety Regulatory Project Manager, at (240) 402-4932 or via email at Felicia.diggs@fda.hhs.gov.

Sincerely,

\{See appended electronic signature page\}

Shanthi Marur, M.B.B.S., M.D.
Safety Associate Director (acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

**ENCLOSURES:**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SHANTHI N MARUR
03/22/2021 12:00:00 AM